Collegium Pharmaceutical (NASDAQ:COLL) Rating Reiterated by Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a research note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 12.01% from the company’s current price.

Several other research firms have also weighed in on COLL. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 29th. Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 target price (up previously from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Finally, Truist Financial increased their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Collegium Pharmaceutical Price Performance

COLL stock opened at $35.71 on Thursday. The company’s 50-day moving average price is $36.69 and its two-hundred day moving average price is $30.39. The firm has a market cap of $1.17 billion, a P/E ratio of 30.26 and a beta of 1.03. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical has a 12 month low of $20.83 and a 12 month high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The business had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. On average, analysts anticipate that Collegium Pharmaceutical will post 5.63 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Scott Dreyer sold 23,560 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $32.28, for a total value of $760,516.80. Following the sale, the executive vice president now owns 111,322 shares of the company’s stock, valued at $3,593,474.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.69% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its position in shares of Collegium Pharmaceutical by 68.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after buying an additional 883,380 shares during the period. Penn Capital Management Company LLC bought a new position in shares of Collegium Pharmaceutical in the 4th quarter worth about $9,755,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Collegium Pharmaceutical in the 1st quarter worth about $7,506,000. Assenagon Asset Management S.A. boosted its position in shares of Collegium Pharmaceutical by 178.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after purchasing an additional 272,565 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Collegium Pharmaceutical by 668.2% during the fourth quarter. Marshall Wace LLP now owns 307,030 shares of the specialty pharmaceutical company’s stock worth $7,123,000 after purchasing an additional 267,065 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.